Search
Mequitazine H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175085Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeOxatomide H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175101Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeMethdilazine H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175105Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeThonzylamine H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175118Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typePropiomazine H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175119Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeDimetotiazine H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175137Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeCariprazine H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175156Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeFexofenadine H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175123Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeDimetindene H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175098Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeBepotastine H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175103Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha type